Phase 1 Open-Label Multicenter Study of INCA033890 in Patients with Advanced or Metastatic Solid Tumors

The primary objective of this study is to evaluate the safety and tolerability of **INCA033890** in participants with **advanced or metastatic solid tumors**. This is clinically relevant as it aims to determine the potential adverse effects and establish a safe dosage range for this investigational drug, which is crucial for the development of effective treatment options for patients with these types of tumors.

The clinical trial involves a total of **110 participants** diagnosed with **advanced or metastatic solid tumors**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to encompass a diverse group of individuals to ensure comprehensive data collection and analysis.

The clinical trial is a **Phase 1**, open-label, multicenter study designed to evaluate the investigational product INCA033890 in participants with **advanced or metastatic solid tumors**. The trial is set to commence recruitment on October 2, 2023, and is anticipated to conclude by December 31, 2026. The study does not employ a randomized, double-blind, or controlled design, as it is an open-label trial, allowing both researchers and participants to be aware of the treatment being administered. The trial will involve a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants who meet the inclusion criteria will proceed to the treatment phase, where they will receive the investigational product. Follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment and to assess any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final assessments will be conducted to gather comprehensive data on the treatment's safety and efficacy. The expected length of participant involvement will vary depending on individual response and the progression of the disease. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial aims to gather critical data to inform future research and potential therapeutic applications for individuals with advanced or metastatic solid tumors.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is October 2, 2023, with an anticipated completion by December 31, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials may involve preliminary assessments of efficacy through various measures. These could include symptom improvement scores, biomarker levels, or other relevant clinical indicators. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.